Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: A meta-analysis

Future Oncology

Volumn 11, Issue 1, 2015, Pages 79-90

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Everolimus; fatigue; hyperglycemia; meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; EVEROLIMUS; EXEMESTANE; LETROZOLE; OCTREOTIDE; PACLITAXEL; TAMOXIFEN; PROTEIN KINASE INHIBITOR; RAPAMYCIN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOMYOLIPOMA; ASTROCYTOMA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARCINOID SYNDROME; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INCIDENCE; KIDNEY CARCINOMA; LIVER TOXICITY; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOUTH ULCER; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; TUBEROUS SCLEROSIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; NEOPLASMS; PATHOLOGY; RISK FACTOR; TOXIC HEPATITIS;

DRUG-INDUCED LIVER INJURY; FATIGUE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RISK FACTORS; SIROLIMUS;

EID: 84921061457     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.136     Document Type: Review

References (28)

1. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl. Oncol. 3(2), 65-79 (2010).
2. Houghton PJ. Everolimus. Clin. Cancer Res. 16(5), 1368-1372 (2010).
3. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside, J. Egypt. Natl Canc. Inst. 25(4), 165-171 (2013).
4. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med. Oncol. 30(3), 655 (2013).
5. Huober J, Fasching PA, Hanusch C et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab-results of the randomised GeparQuinto study (GBG 44). Eur. J. Cancer 49(10), 2284-2293 (2013).
6. Afinitor® (everolimus) tablets for oral administration, package insert, Novartis Pharma AG, Stein, Switzerland (2012).
7. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
8. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006-1012 (2009).
9. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006). http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003).
11. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled Phase 3 trial. Lancet 381(9861), 125-132 (2013).
12. Ohtsu A, Ajani JA, Bai YX et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 study. J. Clin. Oncol. 31(31), 3935-3943 (2013).
13. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869), 817-824 (2013).
14. Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30(22), 2718-2724 (2012).
15. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529. (2012).
16. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet 378(9808), 2005-2012 (2011).
17. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514-523 (2011).
18. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630-2637 (2009).
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177-188 (1986).
20. Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature; Dig. Dis. Sci. 58(12), 3389-3396 (2013).
21. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
22. Finn RS. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer 1(3-4), 247-256 (2012).
23. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 3(2), 295-304 (2002).
24. Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J. Transplant. 2(5), 74-83 (2012).
25. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J. Hum. Hypertens. 27(10), 601-611 (2013).
26. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit. Rev. Oncol. Hematol. 91(1), 1-8 (2014).
27. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev. Anticancer Ther. 14(6), 751-760 (2014).
28. Sivendran S, Agarwal N, Gartrell B et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev. 40(1), 190-196 (2014).